"There's a potential for a more nuanced approach to screening where you assess baseline at 40 for all races, so that you can then determine who needs to be screened regularly or not," says Adam Murphy, MD, MBA, MSCI.
In this video, Adam Murphy, MD, MBA, MSCI, discusses potential legislative directions for PSA screening recommendations moving forward from the 2023 AUA Summit, where he was part of the discussion "Breaking Down Barriers to PSA Screening". Murphy represented R. Frank Jones Urological Society at the Summit, and he is currently an assitant professor of urology at Northwestern University's Feinberg School of Medicine in Chicago, Illinois.
Video Transcript:
The data behind Black men and men with a family history of prostate cancer is clear that they have increased risk between the ages 40 and 54. That, coupled with the fact that Black men have twice the mortality rate, even at low-risk disease, means that earlier disease detection is really important for Black men and men with family history too. There are arguments to be made where getting a baseline PSA tests at age 40, and figuring out if the patient is above or below median for their age group can also detect 90% of the men who would die of prostate cancer.
Having access to PSA screening at least a couple of times in the 40 to 54 age range would be helpful for all men. There's a potential for a more nuanced approach to screening where you assess baseline at 40 for all races, so that you can then determine who needs to be screened regularly or not. The way that it currently defines high-risk is just Black and men with family history. Expanding that to people who are above median for their PSA for their age range would be helpful for future legislation.
This transcription has been edited for clarity.
FDA greenlights phase 3 study of LAE201 in mCRPC
May 23rd 2024"Since the phase 2 data of the combination therapy of LAE002 (afuresertib) plus LAE001 demonstrated encouraging anti-tumor activity and safety profile in patients with mCRPC, a following phase 3 pivotal trial design has been discussed with the US FDA and the approval for the protocol has been received this month," said Yong Yue, MD, PhD.
Galen Prostate shows potential to enhance prostate cancer detection
May 20th 2024"We were deeply impressed by Galen's performance in the study, that based on our validation, clearly showed how Ibex can support our clinicians in improving diagnostic quality and efficiency, and as a result we have decided to implement it routinely,” says Junya Fukuoka, MD, PhD.